# Efficacy of the Alpha 2 Agonist Dexmedetomidine for Sympathetic Deactivation in REfractory Septic Shock

> **NCT07569536** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Hospices Civils de Lyon** · enrollment: 360 (estimated)

## Conditions studied

- Septic Shock, Vasopressor Resistance

## Interventions

- **DRUG:** Dexmedetomidine 100 µg/mL, intravenous solution
- **OTHER:** Stardard care

## Key facts

- **NCT ID:** NCT07569536
- **Lead sponsor:** Hospices Civils de Lyon
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-09-01
- **Primary completion:** 2028-10-01
- **Final completion:** 2028-12-01
- **Target enrollment:** 360 (ESTIMATED)
- **Last updated:** 2026-05-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07569536

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07569536, "Efficacy of the Alpha 2 Agonist Dexmedetomidine for Sympathetic Deactivation in REfractory Septic Shock". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07569536. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*